The natural history of HSV-2 infection and the temporal relationship between HSV-2 and HIV shedding in a population of high-risk women, Tanzania

Size: px
Start display at page:

Download "The natural history of HSV-2 infection and the temporal relationship between HSV-2 and HIV shedding in a population of high-risk women, Tanzania"

Transcription

1 The natural history of HSV-2 infection and the temporal relationship between HSV-2 and HIV shedding in a population of high-risk women, Tanzania Final report June 2009 Dr Deborah Watson-Jones Current address: Department of Infectious & Tropical Diseases London School of Hygiene & Tropical Medicine Keppel Street, London Deborah.watson-jones@lshtm.ac.uk Previous address: AMREF, P.O. Box 1482 Mwanza, Tanzania. Dr Clare Tanton Current address: Centre for Sexual Health & HIV Research University College London Mortimer Market Centre Off Capper Street, London ctanton@gum.ucl.ac.uk Previous address: National Institute for Medical Research, Mwanza, Tanzania / London School of Hygiene & Tropical Medicine, Keppel Street, London

2 Index 1. Summary Aims Collaborators Collaborating organisations Principal Investigator & Co-investigators Funding Overview of the study Results Recruitment & follow-up Study population Aim: to describe the natural history of HSV-2 infection in HIV seronegative and HIV seropositive women Aim: to examine the variability in HSV-2 and HIV shedding and any modifying effect of HSV suppressive therapy Aim: to examine the temporal relationship between HSV-2 and HIV genital shedding Conclusions References

3 1. Summary This report summarises the work carried out on a small sub-study (NIMR/HQ/R.8a/Vol. IX/367) nested within a randomised controlled trial conducted in north-west Tanzania. This is the final report of this study, the fieldwork for which was completed in October Aims The aims of this sub-study were to: describe the natural history of HSV-2 infection in HIV seronegative and HIV seropositive high-risk women in Tanzania examine the variability in HSV-2 and HIV shedding in high-risk women in Tanzania and any modifying effect of HSV suppressive therapy (with aciclovir) examine the temporal relationship between HSV-2 and HIV genital shedding by comparing HIV shedding during and immediately following a period of HSV-2 shedding and between periods of HSV shedding 2. Collaborators 2.1. Collaborating organisations The following organisations are all collaborators for this study: African Medical & Research Foundation (AMREF), Tanzania National Institute for Medical Research (NIMR), Tanzania London School of Hygiene and Tropical Medicine (LSHTM), UK Université Pierre & Marie Curie (UPMC), France 2.2. Principal Investigator & Co-investigators The principal investigator for this study is: Dr Deborah Watson-Jones, AMREF, Mwanza. The Co-investigators / collaborators are: Dr Clare Tanton, LSHTM, UK & NIMR, Tanzania Mr John Changalucha, NIMR, Tanzania Dr Helen Weiss, LSHTM, UK Professor Richard Hayes, LSHTM, UK Professor David Ross, LSHTM, UK Professor Laurent Belec, Inserm U743, France Dr Jerome Legoff, Inserm U743, France - 3 -

4 2.3. Funding This study was funded by the Medical Research Council (MRC), UK. 3. Overview of the study This sub-study was nested within a double-blind placebo-controlled trial of HSV suppressive therapy with aciclovir (400mg b.i.d) which was carried out in the Mwanza, Shinyanga and Mara Regions in northwest Tanzania. The trial s aims were to determine the effect of aciclovir 400mg b.i.d on both HIV acquisition, among women who were initially HSV-2 seropositive but HIV-1 seronegative, and genital shedding of HIV, among women who were initially seropositive for both HSV-2 and HIV. This trial found no effect of aciclovir on either HIV acquisition [1] or genital HIV shedding (Tanton et al, submitted). For this sub-study, a sample of women already enrolled in this RCT and living at two of the sites (Geita Town and Kakola) were seen three times per week for four weeks to collect cervical, vaginal and external skin swabs. Data were collected between August and October Swabs were tested using PCR for quantity of HIV-1 RNA (cervical and vaginal swabs) and HSV DNA (cervical, vaginal and vulval/perineal/perianal). 4. Results 4.1. Recruitment & follow-up Of the 124 women given information on the sub-study at their 18 month appointment, 78 were enrolled at the later enrolment appointment. Of the 77 women who attended at least 2 visits and therefore whose data is used in this analysis, 50 were HIV negative (26 on placebo and 24 on aciclovir) and 27 were HIV positive (13 on placebo and 14 on aciclovir). Follow-up by treatment arm and HIV status is shown in Table 1. Follow-up was 95% or over in each group. Table 1 Follow-up of the study population by treatment allocation Total no. of visits attended Proportion of expected visits attended No. / % HIV negative Aciclovir No. / % No. / % HIV positive Aciclovir No. / % % 95% 99% 95% - 4 -

5 4.2. Study population Characteristics of the population are shown in Table 2. The mean age was 29 years and approximately half of the women were divorced or separated. Median age at first sex was 16 years and median lifetime number of sexual partners was 5. A history of genital ulcers was reported by 30% of the women and 21% reported an episode of genital ulcer disease in the last year. HIV negative and HIV positive women were similar for most characteristics. Table 2 Key characteristics of the women enrolled in the sub-study, by HIV-1 status 1 Characteristic HIV seronegative (N=50) HIV seropositive (N=27) All participants (N=77) Socio-demographic characteristics Median age (IQR), yrs 29 (26-32) 30 (25-34) 29 (26-33) Marital status Single 6 (12.0) 4 (14.8) 10 (13.0) Married / living as married 16 (32.0) 4 (14.8) 20 (26.0) Divorced / separated 24 (48.0) 15 (55.6) 39 (50.7) Widowed 4 (8.0) 4 (14.8) 8 (10.4) Behavioural characteristics Median age at first sex (IQR), yrs 16 (15-18) 16 (15-17) 16 (15-18) Median no. lifetime partners 4 (3-5) 6 (4-20) 5 (3-7) (IQR), yrs No. of times cleanses vagina per day Doesn t cleanse 20 (40.0) 9 (33.3) 29 (37.7) (26.0) 8 (29.6) 21 (27.2) 3 17 (34.0) 10 (37.0) 27 (35.1) Clinical characteristics History of genital ulcers / 17 (34.0) 6 (22.2) 23 (29.9) blisters Episode of GUD in the last yr 12 (24.0) 4 (15.4) 16 (21.1) Biological characteristics Mean plasma HIV RNA load 2 (SD), log 10 copies/ml (1.13) - Cervico-vaginal HIV-1 RNA 2 detected - 14 (58.3) - 1 Variables collected at enrolment to the main trial; 2 Among those HIV positive at enrolment to the main trial. Reported adherence during the sub-study was good with most women self-reporting taking the correct number of tablets at each visit: 84% (42/50) of HIV negative women and 85% (23/27) of HIV positive women. During the 3 month interval of the main trial within which this one month sub-study was nested, 52% of HIV negative women and 48% of HIV positive women had adherence of 90% or more

6 4.3. Aim: to describe the natural history of HSV-2 infection in HIV seronegative and HIV seropositive women The natural history of HSV-2 infection is described in the 26 HIV negative women in the placebo arm and the 13 HIV positive women in the placebo arm Frequency of HSV shedding In HIV negative women, HSV DNA was detected on 33 (11%) of days when samples were taken compared to 30 (19%) of days in the HIV positive women. Of the HIV negative women, 50% had HSV DNA detected from at least one swab during the follow-up period while 70% of HIV positive women had HSV DNA detected at least once (Figure 1). Figure 1 Graph to show proportion of visits women had HSV DNA detected by treatment allocation percent HIV negative HIV positive None <25% 25-<50% 50-<75% There were a total of 19 episodes of HSV shedding (where HSV DNA was detected from at least one site at consecutive visits) in HIV negative women and 16 in HIV positive women. Most episodes lasted only one visit in both HIV negative and HIV positive women. Among those women with HSV DNA detectable during at least one visit, the total number of episodes of HSV DNA shedding ranged from 1-3 in both HIV negative and HIV positive women

7 Sites of HSV reactivation The most common site of HSV reactivation was the vulva/perineal/perianal area in both HIV negative and HIV positive women (Figure 2) followed by the vagina and then the cervix. Figure 2 Percentage of days HSV DNA was detected from each site, by HIV status Percentage days positive Cervical Vaginal Vulval/perineal/perianal 2 0 HIV negative HIV positive Table 3 shows the rates of HSV DNA shedding by site and by whether HSV symptoms were also present. Most shedding was sub-clinical (ie there were no ulcers present when the HSV DNA was detected). Ulcers were present on only 3 days in HIV negative women and 4 days in HIV positive women. During the 7 visits when ulcers were present, there was only one visit when HSV DNA was not detected. Table 3 Rates of total, clinical and subclinical HSV DNA detection by site sampled No. positive / No. visits sampled (%) HIV negative HIV positive Any Clinical 2/3 (66.7) 4/4 (100) Sub-clinical 31/306 (10.1) 26/151 (17.2) Total 33/309 (10.7) 30/155 (19.4) Cervical Clinical 2/3 (67) 4/4 (100) Sub-clinical 14/306 (4.6) 11/151 (7.3) Total 16/309 (5.2) 15/155 (9.7) Vaginal Clinical 2/3 (67) 4/4 (100) Sub-clinical 19/306 (6.2) 14/151 (9.3) Total 21/309 (6.8) 18/155 (11.6) Vulval/perineal/perianal Clinical 2/3 (67) 4/4 (100) Sub-clinical 29/306 (9.5) 22/151 (14.6) Total 31/309 (10.0) 26/155 (16.8) In HIV negative women, of the 33 days when HSV DNA was detected, detection was from all sites at 42% of these days. Of the 30 visits when HSV DNA was detected in HIV positive women, it was detected at all sites at 43% of visits (Figure 3). Most episodes of shedding - 7 -

8 involved the vulval/perineal/perianal area. There were few visits where HSV DNA was detected from only the cervix or the vagina. Figure 3 Sites from which HSV DNA was detected at the visits where HSV DNA was detected from at least one site HIV positive HIV negative All sites Vulval/perineal/perianal & cervix Vulval/perineal/perianal & vagina Vulval/perineal/perianal only Cervix & vagina Cervix only Vagina only 0% 20% 40% 60% 80% 100% Clinical and sub-clinical HSV DNA detection Few HSV shedding visits were associated with genital ulcers. In HIV negative women, 31 out of 33 days when HSV was detected were subclinical. In HIV positive women 26 out of 30 episodes were sub-clinical. The overall rate of subclinical shedding was 10.1% in HIV negative and 17.2% in HIV positive women (Table 3) Aim: to examine the variability in HSV-2 and HIV shedding and any modifying effect of HSV suppressive therapy Description of genital HSV DNA shedding As described in section 0, HSV shedding varied greatly by individual and also occurred at a higher rate in HIV positive women. Aciclovir is expected to reduce HSV shedding. The effect of aciclovir on overall and site specific shedding is shown in Table 4. For HIV negative women there is a significant decrease in HSV shedding overall and at each site. However, for HIV positive women HSV shedding rates are similar in those on placebo and aciclovir

9 Table 4 Effect of aciclovir on overall and site specific shedding by HIV status (N=309) HIV negative Aciclovir (N=275) visits HSV DNA detected Any swab 33 (11) 9 (3) OR 1 (95%CI) (N=155) HIV positive Aciclovir (N=160) (19) 23 (14) (0.12, 0.66) P interaction (treatment & HIV status) = 0.17 Cervical swabs (5) 3 (1) 15 (10) 15 (9) (0.05, 0.82) P interaction = 0.09 Vaginal swabs (7) 6 (2) 18 (12) 16 (10) (0.10, 0.95) P interaction = 0.22 Vulval/perineal/ (10) 3 (1) 26 (17) 17 (11) perianal swabs (0.03, 0.35) P interaction = OR for the effect of aciclovir on HSV DNA detection compared to placebo. OR 1 (95%CI) 0.69 (0.26, 1.85) 0.97 (0.29, 3.23) 0.85 (0.25, 2.88) 0.59 (0.18, 1.92) Similarly, in HIV negative women, aciclovir reduced the HSV viral load in visits where HSV was detected, but there was no reduction for HIV positive women (Figure 4). Figure 4 Effect of aciclovir on frequency of HSV DNA detection by HIV status HIV negative HIV positive Percent None <25% 25-<50% 50-<75% None <25% 25-<50% 50-<75% Aciclovir The variability in HSV DNA detection and viral load is shown for each HIV negative woman with detectable HSV DNA in Figure 5. In the placebo arm, episodes of HSV shedding often involved shedding from more than one site, high viral loads and persisted for more than one visit, while in the aciclovir arm episodes tended to involve only one site and be shorter

10 Figure 5 Quantity of cervical, vaginal and perineal/perianal HSV DNA detected at each visit for each HIV negative participant with at least one visit with detectable HSV DNA HSV DNA (log10 copies/swab) Day of follow-up Cervical Perineal/perianal Vaginal GUD Acyclovir HSV DNA (log10 copies/swab) Day of follow-up Cervical Perineal/perianal Vaginal GUD The variability in HSV shedding in HIV positive women is shown in Figure 6. Unlike for the HIV negative women, there is no apparent difference by treatment arm. In both arms some episodes lasted only one visit while for other women, shedding episodes were longer in duration. Viral loads in both arms were similar

11 Figure 6 Quantity of cervical, vaginal and perineal/perianal HSV DNA detected at each visit for each HIV positive participant with at least one visit with detectable HSV DNA HSV DNA (log10 copies/swab) Day of follow-up Cervical Perineal/perianal Vaginal GUD Acyclovir HSV DNA (log10 copies/swab) Day of follow-up Cervical Perineal/perianal Vaginal GUD Description of genital HIV RNA shedding In the following section, we describe HIV shedding in the 27 HIV positive women (13 on placebo and 14 on acyclovir). HIV RNA was detected during at least one visit in 84.6% of women in the placebo and 92.9% of women in the acyclovir arm. HIV shedding was less variable than HSV shedding. Rates and quantities of HIV shedding were similar in the placebo and acyclovir arms (Table 5)

12 Table 5 Summary of cervical & vaginal HIV-1 RNA detection and viral load overall and by treatment allocation / Mean (SD) Acyclovir / Mean (SD) Cervical swabs Per woman N=13 N=14 HIV-1 RNA detection No visits 2 (15) 1 (7) <50% visits 5 (38) 6 (43) 50-99% visits 3 (23) 4 (29) All visits 3 (28) 3 (21) Per visit N=155 N=160 Visits HIV-1 RNA detected 81 (52) 85 (53) Mean quantity (±SD) log 10 1 copies/ml 2.95 (0.59) 2.97 (0.54) Vaginal swabs Per woman N=13 N=14 HIV-1 RNA detection No visits 2 (15) 6 (43) <50% visits 8 (62) 6 (43) 50-99% visits 2 (15) 2 (14) All visits 1 (8) 0 Per visit analysis N=155 N=160 Visits HIV-1 RNA detected 44 (28) 31 (19) Mean quantity (±SD) log 10 1 copies/ml 3.06 (0.69) 2.71 (0.43) 1 Among those swabs with detectable HIV-1 RNA 4.5. Aim: to examine the temporal relationship between HSV-2 and HIV genital shedding Data from the placebo arm were visually examined to describe the longitudinal relationship between HSV and HIV shedding. This is shown in Figure 7. There was no pattern in HIV RNA quantity in relation to HSV shedding. Figure 7 Variation in cervical and vaginal HIV-1 RNA loads in women with HSV DNA detected at one or more visits. Visits where HSV DNA was detected are marked with an x HIV-1 RNA (log10 copies/swab) Day of follow-up Cervical Vaginal GUD HSV detected Menstrual blood present

13 5. Conclusions Follow-up in this small sub-study nested within a randomised controlled trial was good. HSV reactivation (shedding) was found to vary greatly between individuals. HIV positive women were more likely to shed HSV than HIV negative women. Shedding was common over the 12 visits, 50% of HIV negative women and 70% of HIV positive women had HSV DNA detected at least once. Rates of shedding were similar to those observed in other studies [2]. Most HSV shedding was observed to be sub-clinical, ie not associated with symptoms. The use of episodic therapy for HSV recurrences within this population would therefore only affect a small proportion of total HSV shedding. In this sub-study, while acyclovir reduced HSV shedding rates in HIV negative women, it did not appear to have an impact in HIV positive women. Although adherence rates were similar in HIV negative and HIV positive women, adherence may not have been high enough for adequate HSV suppression in the HIV positive women. 6. References 1. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008;358: Nagot N, Foulongne V, Becquart P, et al. Longitudinal assessment of HIV-1 and HSV-2 shedding in the genital tract of West African women. J Acquir Immune Defic Syndr 2005;39:

Patterns of herpes simplex virus shedding over 1 month and the impact of acyclovir and HIV in HSV-2-seropositive women in Tanzania

Patterns of herpes simplex virus shedding over 1 month and the impact of acyclovir and HIV in HSV-2-seropositive women in Tanzania 1 London School of Hygiene and Tropical Medicine, London, UK 2 National Institute for Medical Research (NIMR), Mwanza, Tanzania 3 Laboratoire de Microbiologie, Hôpital Saint Louis, Paris, France 4 Départment

More information

Herpes virus co-factors in HIV infection

Herpes virus co-factors in HIV infection Herpes virus co-factors in HIV infection Dr Jane Deayton Barts and the London Queen Mary School of Medicine Introduction Herpes viruses very common and often coexist with HIV Establish life-long latent

More information

Professor Adrian Mindel

Professor Adrian Mindel Causes of genital ulceration viruses and others Professor Adrian Mindel University of Sydney VIM 16 th August 2012 Outline Definition Causes Epidemiology Diagnosis Definition of genital ulcer A defect

More information

Sexually Transmitted Infection Treatment and HIV Prevention

Sexually Transmitted Infection Treatment and HIV Prevention Sexually Transmitted Infection Treatment and HIV Prevention Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine STI Treatment and HIV Prevention.

More information

Episodic Therapy for Genital Herpes in Sub-Saharan Africa: A Pooled Analysis from Three Randomized Controlled Trials

Episodic Therapy for Genital Herpes in Sub-Saharan Africa: A Pooled Analysis from Three Randomized Controlled Trials Episodic Therapy for Genital Herpes in Sub-Saharan Africa: A Pooled Analysis from Three Randomized Controlled Trials Helen A. Weiss 1 *, Gabriela Paz Bailey 2, Sam Phiri 3, Gerard Gresenguet 4, Jerome

More information

Reducing the Sexual Transmission of Genital Herpes

Reducing the Sexual Transmission of Genital Herpes CLINICAL GUIDELINE Reducing the Sexual Transmission of Genital Herpes Compiled by Adrian Mindel Introduction People diagnosed with genital herpes usually have many questions and concerns, a key one being

More information

Outline. HIV and Other Sexually Transmitted Infections. Gonorrhea Epidemiology. Epidemiology 11/2/2012

Outline. HIV and Other Sexually Transmitted Infections. Gonorrhea Epidemiology. Epidemiology 11/2/2012 HIV and Other Sexually Transmitted Infections Tanya Kowalczyk Mullins, MD, MS Division of Adolescent Medicine Cincinnati Children s Hospital Medical Center Outline Epidemiology of select STIs and HIV STIs

More information

The Synergy between HIV and other STIs

The Synergy between HIV and other STIs Training Course in Sexual and Reproductive Health Research 2017 Module: Sexually transmitted infections, HIV/AIDS The Synergy between HIV and other STIs Alberto Matteelli Brescia University Sexual Transmission

More information

People with genital herpes require enough information and medication (when indicated) to self-manage their condition.

People with genital herpes require enough information and medication (when indicated) to self-manage their condition. Genital Herpes Summary of Guidelines Taken from: Guidelines for the Management of Genital Herpes in New Zealand 11th Edition - 2015 www.herpes.org.nz Genital Herpes Key Management Points Genital herpes

More information

Vitamin A Supplementation and Genital Shedding of Herpes Simplex Virus among HIV-1 Infected Women: A Randomized Clinical Trial

Vitamin A Supplementation and Genital Shedding of Herpes Simplex Virus among HIV-1 Infected Women: A Randomized Clinical Trial MAJOR ARTICLE Vitamin A Supplementation and Genital Shedding of Herpes Simplex Virus among HIV-1 Infected Women: A Randomized Clinical Trial Jared M. Baeten, 1,a R. Scott McClelland, 2 Lawrence Corey,

More information

Testing for Herpes Simplex Infections Getting it DONE!

Testing for Herpes Simplex Infections Getting it DONE! Testing for Herpes Simplex Infections Getting it DONE! Tens of millions of people have been diagnosed with herpes infections Genital Herpes Issues The Most Common Cause of Genital Ulceration is is Herpes

More information

Effect of Herpes Simplex Suppression on Incidence of HIV among Women in Tanzania

Effect of Herpes Simplex Suppression on Incidence of HIV among Women in Tanzania The new england journal of medicine original article Effect of Herpes Simplex Suppression on Incidence of HIV among Women in Tanzania Deborah Watson-Jones, M.D., Ph.D., Helen A. Weiss, Ph.D., Mary Rusizoka,

More information

A multi-faceted approach to adherence a broader perspective. Wits Institute (formerly RHRU and ECHO) MTN Regional Meeting, October 2010

A multi-faceted approach to adherence a broader perspective. Wits Institute (formerly RHRU and ECHO) MTN Regional Meeting, October 2010 A multi-faceted approach to adherence a broader perspective Wits Institute (formerly RHRU and ECHO) MTN Regional Meeting, October 2010 Adherence in HIV prevention trials Adherence to investigational product

More information

Rush to Judgment Understanding the STI-HIV Trials

Rush to Judgment Understanding the STI-HIV Trials Rush to Judgment Understanding the STI-HIV Trials Larry Sawers American University, Washington, DC, USA Eileen Stillwaggon Gettysburg College, Gettysburg, PA, USA 7th IAEN Preconference Washington, DC,

More information

Effect of Herpes Simplex Suppression on Incidence of HIV among Women in Tanzania

Effect of Herpes Simplex Suppression on Incidence of HIV among Women in Tanzania Europe PMC Funders Group Author Manuscript Published in final edited form as: N Engl J Med. 2008 April 10; 358(15): 1560 1571. doi:10.1056/nejmoa0800260. Effect of Herpes Simplex Suppression on Incidence

More information

Persistent Genital Herpes Simplex Virus-2 Shedding Years Following the First Clinical Episode

Persistent Genital Herpes Simplex Virus-2 Shedding Years Following the First Clinical Episode MAJOR ARTICLE Persistent Genital Herpes Simplex Virus-2 Shedding Years Following the First Clinical Episode Warren Phipps, 1,6 Misty Saracino, 2 Amalia Magaret, 2,5 Stacy Selke, 2 Mike Remington, 2 Meei-Li

More information

Pregnancy and contraceptive use among women participating in an HIV prevention trial in Tanzania

Pregnancy and contraceptive use among women participating in an HIV prevention trial in Tanzania < Additional figures are published online only. To view these files please visit the journal online (http://sti.bmj. com/content/early/recent). 1 London School of Hygiene and Tropical Medicine, London,

More information

Meeting report. Contents. Preface 3 Acknowledgments 4 Controlling HSV 2 infection for the reduction of HIV 5

Meeting report. Contents. Preface 3 Acknowledgments 4 Controlling HSV 2 infection for the reduction of HIV 5 WHO/RHR/11.37 Meeting report Report of the expert consultation and review of the latest evidence to update guidelines for the management of sexually transmitted infections Meeting report Contents Preface

More information

MEMA kwa Vijana Adolescent Trial, Mwanza, Tanzania

MEMA kwa Vijana Adolescent Trial, Mwanza, Tanzania MEMA kwa Vijana MEMA kwa Vijana Good things for young people Lessons Learned David Ross for John Changalucha, Bernadette Cleophas-Mazige, Aoife Doyle, Richard Hayes, Kaballa Maganja, Angela Obasi, Mary

More information

GENDER AND HIV IN LIMPOPO PROVINCE. Mohammed Abdosh Ali

GENDER AND HIV IN LIMPOPO PROVINCE. Mohammed Abdosh Ali GENDER AND HIV IN LIMPOPO PROVINCE Mohammed Abdosh Ali Research report submitted to the Faculty of Health Sciences, University of the Witwatersrand, in partial fulfillment of the requirements for the Degree

More information

GENITAL HERPES. 81.1% of HSV-2 infections are asymptomatic or unrecognized. Figure 14 HSV-2 seroprevalence among persons aged years by sex.

GENITAL HERPES. 81.1% of HSV-2 infections are asymptomatic or unrecognized. Figure 14 HSV-2 seroprevalence among persons aged years by sex. GENITAL HERPES Genital herpes is a chronic, lifelong, sexually transmitted disease caused by herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2). HSV-1 typically causes small, painful, fluid-filled,

More information

METHODS. Herpes simplex virus type 2 (HSV-2) is common among persons infected with HIV-1 (seroprevalence, 50% 90%) [1]. HSV-2 reactivation,

METHODS. Herpes simplex virus type 2 (HSV-2) is common among persons infected with HIV-1 (seroprevalence, 50% 90%) [1]. HSV-2 reactivation, BRIEF REPORT Herpes Simplex Virus (HSV) Suppressive Therapy Decreases Plasma and Genital HIV-1 Levels in HSV-2/HIV-1 Coinfected Women: A Randomized, Placebo-Controlled, Cross-Over Trial Jared M. Baeten,

More information

Genital Herpes in the STD Clinic

Genital Herpes in the STD Clinic Genital Herpes in the STD Clinic Christine Johnston, MD, MPH Last Updated: 5/23/2016 uwptc@uw.edu uwptc.org 206-685-9850 Importance of HSV HSV is the leading cause of GUD - HSV is very common HSV-2: 16%

More information

Oral Manifestations of HIV: Case Studies

Oral Manifestations of HIV: Case Studies NORTHWEST AIDS EDUCATION AND TRAINING CENTER Oral Manifestations of HIV: Case Studies David Spach, MD Principal Investigator and Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious

More information

Maternal oral CMV recurrence following postnatal primary infection in infants

Maternal oral CMV recurrence following postnatal primary infection in infants Maternal oral CMV recurrence following postnatal primary infection in infants I. Boucoiran, B. T. Mayer, E. Krantz, S. Boppana, A. Wald, L. Corey, C.Casper, J. T. Schiffer, S. Gantt No conflict of interest

More information

Can HPV, cervical neoplasia or. HIV transmission?

Can HPV, cervical neoplasia or. HIV transmission? Interactions between HPV and HIV: STIs and HIV shedding, regulation of HPV by HIV, and HPV VLP influence upon HIV Jennifer S. Smith Department of Epidemiology pd University of North Carolina Can HPV, cervical

More information

Response to Acyclovir in Immunocompetent and Immunocompromised herpes genitalis patients

Response to Acyclovir in Immunocompetent and Immunocompromised herpes genitalis patients International Journal of Sciences & Applied Research www.ijsar.in Response to Acyclovir in Immunocompetent and Immunocompromised herpes genitalis patients Duggirala S.S. Srinivas Prasad*, T.V. Narasimha

More information

Herpes Simplex Viruses: Disease Burden. Richard Whitley The University of Alabama at Birmingham Herpes Virus Infection and Immunity June 18-20, 2012

Herpes Simplex Viruses: Disease Burden. Richard Whitley The University of Alabama at Birmingham Herpes Virus Infection and Immunity June 18-20, 2012 Herpes Simplex Viruses: Disease Burden Richard Whitley The University of Alabama at Birmingham Herpes Virus Infection and Immunity June 18-20, 2012 Mucocutaneous HSV Infections Life-Threatening HSV Diseases

More information

HIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP

HIV: Pregnancy in Serodiscordant Couple. Dr Chow TS ID Clinic HPP HIV: Pregnancy in Serodiscordant Couple Dr Chow TS ID Clinic HPP Sexual Reproductive Health and Rights The recognition of the sexual and reproductive health and rights (SRHR) of all individuals and couples

More information

Downloaded from:

Downloaded from: Kapiga, SH; Ewings, FM; Ao, T; Chilongani, J; Mongi, A; Baisley, K; Francis, S; Andreasen, A; Hashim, R; Watson-Jones, D; Changalucha, J; Hayes, R (2013) The Epidemiology of HIV and HSV-2 Infections among

More information

Herpesvirus infections in pregnancy

Herpesvirus infections in pregnancy Herpesvirus infections in pregnancy Dr. med. Daniela Huzly Institute of Virology University Medical Center Freiburg, Germany Herpes simplex virus 1+2 Risk in pregnancy and at birth Primary infection in

More information

Buve, A., H. A. Weiss, et al. (2001). The epidemiology of trichomoniasis in women in four African cities. Aids 15 Suppl 4: S89-96.

Buve, A., H. A. Weiss, et al. (2001). The epidemiology of trichomoniasis in women in four African cities. Aids 15 Suppl 4: S89-96. Behets, F., J. Andriamiadana, et al. (2001). Sexually transmitted infections and associated socio-demographic and behavioural factors in women seeking primary care suggest Madagascar's vulnerability to

More information

Downloaded from:

Downloaded from: Todd, J; Riedner, G; Maboko, L; Hoelscher, M; Weiss, HA; Lyamuya, E; Mabey, D; Rusizoka, M; Belec, L; Hayes, R (2013) Effect of Genital Herpes on Cervicovaginal HIV Shedding in Women Co-Infected with HIV

More information

Population attributable fraction of genital inflammation and ulceration in HIV risk among discordant couples, Zambia,

Population attributable fraction of genital inflammation and ulceration in HIV risk among discordant couples, Zambia, Population attributable fraction of genital inflammation and ulceration in HIV risk among discordant couples, Zambia, 1994-2012 10 th International Workshop on HIV Transmission Kristin M. Wall, PhD kmwall@emory.edu

More information

Importance of Viral Suppression to Reduce HIV Transmission: Recent Evidence

Importance of Viral Suppression to Reduce HIV Transmission: Recent Evidence Importance of Viral Suppression to Reduce HIV Transmission: Recent Evidence Toye Brewer, MD Co-Director, Fogarty International Training Program University of Miami Miller School of Medicine Viral suppression

More information

Models for HSV shedding must account for two levels of overdispersion

Models for HSV shedding must account for two levels of overdispersion UW Biostatistics Working Paper Series 1-20-2016 Models for HSV shedding must account for two levels of overdispersion Amalia Magaret University of Washington - Seattle Campus, amag@uw.edu Suggested Citation

More information

Summary Measures of Adherence Using Pill Counts in Two HIV Prevention Trials: The Need for Standardisation in Reporting

Summary Measures of Adherence Using Pill Counts in Two HIV Prevention Trials: The Need for Standardisation in Reporting AIDS Behav (2013) 17:3108 3119 DOI 10.1007/s10461-013-0542-9 ORIGINAL PAPER Summary Measures of Adherence Using Pill Counts in Two HIV Prevention Trials: The Need for Standardisation in Reporting Kathy

More information

Professor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA

Professor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA 17 TH ANNUAL CONFERENCE OF THE BRITISH HIV ASSOCIATION (BHIVA) Professor Thomas Quinn Johns Hopkins Center for Global Health, Maryland, USA 6-8 April 2011, Bournemouth International Centre 17 TH ANNUAL

More information

Contraception & HIV Still searching for answers after >2 decades

Contraception & HIV Still searching for answers after >2 decades Contraception & HIV Still searching for answers after >2 decades R Scott McClelland, MD, MPH University of Washington Inter CFAR Symposium on HIV Research in Women September 20 th 2012 Overview Global

More information

Suitability of simple HIV rapid tests in clinical trials in community-based clinic settings

Suitability of simple HIV rapid tests in clinical trials in community-based clinic settings JCM Accepts, published online ahead of print on 25 February 2009 J. Clin. Microbiol. doi:10.1128/jcm.01998-08 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions. All

More information

Performance of HerpeSelect and Kalon Assays to Detect Antibodies to Herpes Simplex Virus Type 2 ACCEPTED

Performance of HerpeSelect and Kalon Assays to Detect Antibodies to Herpes Simplex Virus Type 2 ACCEPTED JCM Accepts, published online ahead of print on April J. Clin. Microbiol. doi:./jcm.- Copyright, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved. 1 1 1 1 1

More information

Genital Tract Infections in HIV- Infected Pregnant Women in South West London

Genital Tract Infections in HIV- Infected Pregnant Women in South West London Genital Tract Infections in HIV- Infected Pregnant Women in South West London A Hegazi, N Ramskill, M Norbrook, E Dwyer, S Milne, B Nathan, S Esterich, A ElGalib, T Morgan, A Barbour, P Hay St George s

More information

PrEP efficacy the evidence

PrEP efficacy the evidence PrEP efficacy the evidence Dr Michael Brady Consultant, HIV and Sexual Health King s College Hospital, London Medical Director Terrence Higgins Trust PrEP Pre-exposure prophylaxis Tenofovir and emtricitabine

More information

HIV/STDs and Excretion of HIV in Genital Secretions - Implications for sexual transmission. Pietro L. Vernazza, KSSG, St. Gallen, Switzerland

HIV/STDs and Excretion of HIV in Genital Secretions - Implications for sexual transmission. Pietro L. Vernazza, KSSG, St. Gallen, Switzerland HIV/STDs and Excretion of HIV in Genital Secretions - Implications for sexual transmission Pietro L. Vernazza, KSSG, St. Gallen, Switzerland Where it all began... Vogt M, Lancet, 8. March 86 Schultz

More information

Herpes What is it? How is it transmitted? How is it treated?

Herpes What is it? How is it transmitted? How is it treated? Herpes What is it? How is it transmitted? How is it treated? A service provided by page 2 of 12 What is genital herpes? Genital herpes is caused by the herpes simplex virus (HSV). It is a very common virus.

More information

Summary of Results for Laypersons

Summary of Results for Laypersons What was the Study Called? Summary of Results for Laypersons A Phase 2 Dose-Finding Study with ASP2151 in Subjects with Recurrent Episodes of Genital Herpes Why was this Study Needed? Genital herpes is

More information

Ron Gray, MBBS, MFCM, MSc Johns Hopkins University. STIs in an International Setting

Ron Gray, MBBS, MFCM, MSc Johns Hopkins University. STIs in an International Setting This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Community oriented studies. New perspectives

Community oriented studies. New perspectives Community oriented studies. New perspectives Swiss HIV Cohort Study Increased Viral Load Suppression in HIV+ Persons on ART Cohort size: 4624 4852 5045 5279 5556 5830 6121 6418 6526 100 Percent of individuals

More information

Sexually Transmitted Infections in HSV-2 Seropositive women in Sub- Saharan Africa HPTN 039

Sexually Transmitted Infections in HSV-2 Seropositive women in Sub- Saharan Africa HPTN 039 Sexually Transmitted Infections in HSV-2 Seropositive women in Sub- Saharan Africa HPTN 039 Ulrika Makuraj, MBBCH University of Witwatersrand Mentor : Sinead Delany-Moretlwe South Africa 17 May 2018 Introduction

More information

Antivirals and Vaccines: What s old and new in HSV-2 treatment

Antivirals and Vaccines: What s old and new in HSV-2 treatment Antivirals and Vaccines: What s old and new in HSV-2 treatment Christine Johnston, MD, MPH Last Updated: January 19, 2018 uwptc@uw.edu uwptc.org 206-685-9850 Importance of HSV: Why pursue a vaccine? Prevention

More information

Genital Herpes Simplex Virus

Genital Herpes Simplex Virus WHO GUIDELINES FOR THE Treatment of Genital Herpes Simplex Virus Web annex D: Evidence tables and evidence-to-decision frameworks September 2016 The full guidelines are available at: www.who.int/reproductivehealth/publications/rtis/genital-hsv-treatment-guidelines/en/

More information

Time taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART

Time taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART Time taken to reach undetectable viral loads in therapy-naïve HIV patients commencing ART Authors M A Ismail, E Okpo, S Baguley, A Butt, D Brawley, I Tonna 4 University of Aberdeen, MBChB Office, School

More information

HIV 1 Preventive Vaccine Regimen. Community based Trial in Thailand V 144. for the MOPH TAVEG Collaboration

HIV 1 Preventive Vaccine Regimen. Community based Trial in Thailand V 144. for the MOPH TAVEG Collaboration V ALVAC HIV and AIDSVAX B/E Prime Boost HIV 1 Preventive Vaccine Regimen Final Results of the Phase III Community based Trial in Thailand Supachai Rerks Ngarm, Punnee Pittisutthithum, Sorachai Nitayaphan,

More information

Case 1. Case 1. Physical exam

Case 1. Case 1. Physical exam 11/13/2012 Case 28 year-old woman Complains of very painful lesions in vulvar area Increasing severity since 4 days Pain aggravated by urination She has a slight fever and also complains of headache and

More information

The impact of male circumcision on the female-to-male transmission of HIV : Results of the intervention trial : ANRS 1265

The impact of male circumcision on the female-to-male transmission of HIV : Results of the intervention trial : ANRS 1265 The impact of male circumcision on the female-to-male transmission of HIV : Results of the intervention trial : ANRS 1265 Bertran Auvert, INSERM, UVSQ, AP-HP, France Adrian Puren, NICD, South Africa Dirk

More information

(See the editorial commentary by Tanton et al, on pages )

(See the editorial commentary by Tanton et al, on pages ) MAJOR ARTICLE High-dose Valacyclovir HSV-2 Suppression Results in Greater Reduction in Plasma HIV-1 Levels Compared With Standard Dose Acyclovir Among HIV-1/HSV-2 Coinfected Persons: A Randomized, Crossover

More information

Herpes: Herpes Cure: Treatments For Genital Herpes And Oral Herpes, Diagnostic Techniques And How To Stay Herpes Free For Life (Health And Fitness

Herpes: Herpes Cure: Treatments For Genital Herpes And Oral Herpes, Diagnostic Techniques And How To Stay Herpes Free For Life (Health And Fitness Herpes: Herpes Cure: Treatments For Genital Herpes And Oral Herpes, Diagnostic Techniques And How To Stay Herpes Free For Life (Health And Fitness Book 2) By Philip Vang, Josh David If you are searching

More information

How HIV prevalence, number of sexual partners and marital status are related in rural Uganda.

How HIV prevalence, number of sexual partners and marital status are related in rural Uganda. How HIV prevalence, number of sexual partners and marital status are related in rural Uganda. Ivan Kasamba (2), Dermot Maher (2), Sam Biraro (2), Heiner Grosskurth (1,2), Jim Todd (1). 1. LSHTM, Keppel

More information

9/29/2014. Genital Ulcer Diseases GENITAL HSV. HSV-2: Primer. Genital Ulcer Diseases Does It Hurt? Painful. Painless. Chancroid Genital herpes simplex

9/29/2014. Genital Ulcer Diseases GENITAL HSV. HSV-2: Primer. Genital Ulcer Diseases Does It Hurt? Painful. Painless. Chancroid Genital herpes simplex Genital Ulcer Diseases Mychelle Y. Farmer, MD, FAAP STD/HIV Prevention Training Center at Johns Hopkins Genital Ulcer Diseases Does It Hurt? Painful Chancroid Genital herpes simplex Painless Syphilis Lymphogranuloma

More information

Valacyclovir and Acyclovir for Suppression of Shedding of Herpes Simplex Virus in the Genital Tract

Valacyclovir and Acyclovir for Suppression of Shedding of Herpes Simplex Virus in the Genital Tract MAJOR ARTICLE Valacyclovir and Acyclovir for Suppression of Shedding of Herpes Simplex Virus in the Genital Tract Rachna Gupta, 1 Anna Wald, 1,2,3,4 Elizabeth Krantz, 3 Stacy Selke, 3 Terri Warren, 5 Mauricio

More information

HIV-1 Transmissions During Asymptomatic Infection: Exploring the Impact of Changes in HIV-1 Viral Load Due to Coinfections

HIV-1 Transmissions During Asymptomatic Infection: Exploring the Impact of Changes in HIV-1 Viral Load Due to Coinfections BRIEF REPORT: EPIDEMIOLOGY AND PREVENTION HIV-1 Transmissions During Asymptomatic Infection: Exploring the Impact of Changes in HIV-1 Viral Load Due to Coinfections Rebecca F. Baggaley, PhD* and T. Déirdre

More information

Answers to those burning questions -

Answers to those burning questions - Answers to those burning questions - Ann Avery MD Infectious Diseases Physician-MetroHealth Medical Center Assistant Professor- Case Western Reserve University SOM Medical Director -Cleveland Department

More information

Prevalence, type and factors associated with HPV infection at multiple sites in young HIV- positive MSM

Prevalence, type and factors associated with HPV infection at multiple sites in young HIV- positive MSM Prevalence, type and factors associated with HPV infection at multiple sites in young HIV- positive MSM On behalf of the HPV MAPS Research Group C Sadlier 1,2, S O Dea 1, S Delamere 1, P Smyth 3, N Myers

More information

NIH Public Access Author Manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2012 June 11.

NIH Public Access Author Manuscript J Acquir Immune Defic Syndr. Author manuscript; available in PMC 2012 June 11. NIH Public Access Author Manuscript Published in final edited form as: J Acquir Immune Defic Syndr. 2001 February 1; 26(2): 170 175. Comparison of Techniques for HIV-1 RNA Detection and Quantitation in

More information

Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world?

Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Antiretroviral Drugs for HIV Seronegative People: It works in trials, what about the real world? Lut Van Damme 11 Oct 2012 1 Disclaimer Gilead donated the study product for the FEM-PrEP trial I participated

More information

Abstract. Burris et al. Health Research Policy and Systems 2011, 9(Suppl 1):S5

Abstract. Burris et al. Health Research Policy and Systems 2011, 9(Suppl 1):S5 RESEARCH Open Access Getting research into policy - Herpes simplex virus type-2 (HSV-2) treatment and HIV infection: international guidelines formulation and the case of Ghana H Burris 1,3*, J Parkhurst

More information

Effect of HSV-2 suppressive therapy on genital tract HIV-1 RNA shedding among women on HAART: A pilot randomized controlled trial

Effect of HSV-2 suppressive therapy on genital tract HIV-1 RNA shedding among women on HAART: A pilot randomized controlled trial Effect of HSV-2 suppressive therapy on genital tract HIV-1 RNA shedding among women on HAART: A pilot randomized controlled trial A.E. Nijhawan, Beth Israel Deaconess Medical Center A.K. Delong, Brown

More information

SUBCLINICAL shedding of herpes simplex virus

SUBCLINICAL shedding of herpes simplex virus 770 THE NEW ENGLAND JOURNAL OF MEDICINE Sept. 21, 1995 VIROLOGIC CHARACTERISTICS OF SUBCLINICAL AND SYMPTOMATIC GENITAL HERPES INFECTIONS ANNA WALD, M.D., M.P.H., JUDITH ZEH, PH.D., STACY SELKE, M.A.,

More information

Downloaded from:

Downloaded from: Foss, AM; Vickerman, PT; Mayaud, P; Weiss, HA; Ramesh, BM; Reza-Paul, S; Washington, R; Blanchard, J; Moses, S; Lowndes, CM; Alary, M; Watts, CH (2011) Modelling the interactions between herpes simplex

More information

Women and Viral Load. Together, we can change the course of the HIV epidemic one woman at a time.

Women and Viral Load. Together, we can change the course of the HIV epidemic one woman at a time. Women and Viral Load Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject What Is Viral Load? Viral load is the amount of HIV (number of viruses

More information

Hormonal Contraception and HIV

Hormonal Contraception and HIV Hormonal Contraception and HIV A ROUNDTABLE AT THE INTEREST WORKSHOP, LUSAKA, 2014 Professor Helen Rees, Wits RHI, Johannesburg, SA Dr Mike Mbizvo, Zimbabwe Dr Chelsea Polis, USAID, Washington Dr Nelly

More information

Fertility Desires/Management of Serodiscordant HIV + Couples

Fertility Desires/Management of Serodiscordant HIV + Couples Fertility Desires/Management of Serodiscordant HIV + Couples William R. Short, MD, MPH Assistant Professor of Medicine Division Of Infectious Diseases Jefferson Medical College of Thomas Jefferson University

More information

Second generation HIV surveillance: Better data for decision making

Second generation HIV surveillance: Better data for decision making Second generation HIV surveillance: Better data for decision making Prof Thomas M Rehle, MD, PhD Human Sciences Research Council, South Africa HAI Conference on Prevention and Control of the HIV Epidemic

More information

Patterns and predictors of dual contraceptive use among sexually active treatment experienced women living with HIV in British Columbia, Canada.

Patterns and predictors of dual contraceptive use among sexually active treatment experienced women living with HIV in British Columbia, Canada. Patterns and predictors of dual contraceptive use among sexually active treatment experienced women living with HIV in British Columbia, Canada. Sophie Patterson 1,2, Wendy Zhang 1, Kate Salters 1, Yalin

More information

Congenital/Neonatal Herpes Simplex Infections

Congenital/Neonatal Herpes Simplex Infections Congenital/Neonatal Herpes Simplex Infections Infectious and Tropical Pediatric Division Department of Child Health Medical Faculty University of Sumatera Utara Herpes Infections Herpes from the Greek

More information

It has been estimated that 90% of individuals

It has been estimated that 90% of individuals Famciclovir for Cutaneous Herpesvirus Infections: An Update and Review of New Single-Day Dosing Indications Manju Chacko, MD; Jeffrey M. Weinberg, MD Infections with herpes simplex virus (HSV) types 1

More information

Summary Guidelines for the Use of Herpes Simplex Virus (HSV) Type 2 Serologies

Summary Guidelines for the Use of Herpes Simplex Virus (HSV) Type 2 Serologies Summary Guidelines for the Use of Herpes Simplex Virus (HSV) Type 2 Serologies Genital herpes is one of the most prevalent sexually transmitted diseases, affecting more than one in five sexually active

More information

Performance of HerpeSelect and Kalon Assays in Detection of Antibodies to Herpes Simplex Virus Type 2

Performance of HerpeSelect and Kalon Assays in Detection of Antibodies to Herpes Simplex Virus Type 2 JOURNAL OF CLINICAL MICROBIOLOGY, June 2008, p. 1914 1918 Vol. 46, No. 6 0095-1137/08/$08.00 0 doi:10.1128/jcm.02332-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Performance

More information

STD Epidemiology. Jonathan Zenilman, MD Johns Hopkins University

STD Epidemiology. Jonathan Zenilman, MD Johns Hopkins University This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Downloaded from:

Downloaded from: Mercer, CH; Tanton, C; Prah, P; Erens, B; Sonnenberg, P; Clifton, S; MacDowall, W; Lewis, R; Field, N; Datta, J; Copas, AJ; Phelps, A; Wellings, K; Johnson, AM (2013) Changes in sexual attitudes and lifestyles

More information

Hormonal Contraception and the Risk of HIV Acquisition

Hormonal Contraception and the Risk of HIV Acquisition Hormonal Contraception and the Risk of HIV Acquisition Charles Morrison, PhD International Conference on Family Planning Kampala, Uganda November 16, 2009 Hormonal Contraception and HIV About 16 million

More information

INTRODUCTION Post-rape HIV acquisition is a huge concern in settings with high prevalence of both HIV and sexual violence. Systematic reviews

INTRODUCTION Post-rape HIV acquisition is a huge concern in settings with high prevalence of both HIV and sexual violence. Systematic reviews EXPLORING THE HEALTH DIFFERENCES BETWEEN WOMEN RAPED AND WOMEN NOT RAPED: ANALYSIS OF BASELINE DATA FROM THE SOUTH AFRICAN RAPE IMPACT COHORT EVALUATION (RICE) STUDY Authors: Naeemah Abrahams, Soraya Seedat,

More information

Genital herpes is caused by infection with the herpes simplex viruses (HSV) of which there are two types (HSV-1 and HSV-2).

Genital herpes is caused by infection with the herpes simplex viruses (HSV) of which there are two types (HSV-1 and HSV-2). ANO-GENITAL HERPES Introduction Genital herpes is caused by infection with the herpes simplex viruses (HSV) of which there are two types (HSV-1 and HSV-2). Definitions Initial episode: First episode with

More information

The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN

The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN The Science behind Preexposure Prophylaxis (PrEP) Yunus Moosa Department of Infectious Diseases UKZN 1 Ongoing HIV transmission despite expanding access to ART SA 18 16 14 12 10 8 6 4 2 0 Treatment exposure

More information

Articles. Vol 371 June 21,

Articles.  Vol 371 June 21, Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial Connie Celum, Anna Wald, James

More information

Effects of Gender, Race, Age & BMI on the Pharmacokinetics of Long-Acting Rilpivirine (RPV-LA) after a Single IM Injection in HIV negative subjects.

Effects of Gender, Race, Age & BMI on the Pharmacokinetics of Long-Acting Rilpivirine (RPV-LA) after a Single IM Injection in HIV negative subjects. Effects of Gender, Race, Age & BMI on the Pharmacokinetics of Long-Acting Rilpivirine (RPV-LA) after a Single IM Injection in HIV negative subjects. Laura Else 1, Akil Jackson 2, Deidre Egan 1, Zeenat

More information

An approach for general practitioners in Australia

An approach for general practitioners in Australia CLINICAL PRACTICE: Therapeutic review Genital herpes An approach for general practitioners in Australia Catriona Ooi, MBBS, BSc(Med), is Registrar, Royal North Shore Hospital and Manly Sexual Health, New

More information

Valtrex prevent the spread of herpes

Valtrex prevent the spread of herpes Home Search Valtrex prevent the spread of herpes 26-9-2002 Sept. 27, 2002 -- The drug Valtrex -- prescribed to prevent recurrences of genital herpes -- may actually help prevent the spread of the virus

More information

HSV Screening: Are Wesley Obstetricians Following the Guidelines? Dawn Boender, PGY4 Taylor Bertschy, PGY3

HSV Screening: Are Wesley Obstetricians Following the Guidelines? Dawn Boender, PGY4 Taylor Bertschy, PGY3 HSV Screening: Are Wesley Obstetricians Following the Guidelines? Dawn Boender, PGY4 Taylor Bertschy, PGY3 Goals To increase obstetrician knowledge regarding HSV screening Institute clinical changes at

More information

B eyond individual benefits, the public health significance

B eyond individual benefits, the public health significance 24 ORIGINAL ARTICLE The potential epidemiological impact of a genital herpes vaccine for women G P Garnett, G Dubin, M Slaoui, T Darcis... See end of article for authors affiliations... Correspondence

More information

Biomedical Prevention Update Thomas C. Quinn, M.D.

Biomedical Prevention Update Thomas C. Quinn, M.D. Biomedical Prevention Update Thomas C. Quinn, M.D. Associate Director of International Research National Institute of Allergy and Infectious Diseases Director, Johns Hopkins Center for Global Health Global

More information

ART for HIV Prevention:

ART for HIV Prevention: ART for HIV Prevention: KENNETH H. MAYER, M.D. Brown University/The Fenway Institute August 22, 2009 APPROACHES TO PREVENT HIV TRANSMISSION DECREASE SOURCE OF INFECTION Barrier Protection Treat STI Antiretroviral

More information

Genital herpes is caused by infection with the herpes simplex viruses (HSV) of which there are two types (HSV-1 and HSV-2).

Genital herpes is caused by infection with the herpes simplex viruses (HSV) of which there are two types (HSV-1 and HSV-2). ANO-GENITAL HERPES What s new in this guideline: Patient counselling: key points to cover HSV in immunosuppressed and HIV positive individuals Suppressive therapy does not require consultant review prior

More information

Can women s narratives on emergent HIV biotechnologies gained during medical research reveal future practice and possibilities?

Can women s narratives on emergent HIV biotechnologies gained during medical research reveal future practice and possibilities? Can women s narratives on emergent HIV biotechnologies gained during medical research reveal future practice and possibilities? Shelley Lees London School of Hygiene and Tropical Medicine biomedical technology

More information

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE Ankamma A,, 2014; Volume 3(5): 510-515 INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE STUDY OF SEROPREVALENCE OF HSV-2 AMONG HIV SEROPOSITIVE INDIVIDUALS AT S.V.R.R.G.G.H TIRUPATI ANKAMMA

More information

Make Love Not Warts Genital Warts

Make Love Not Warts Genital Warts Patricia Wong, MD 735 Cowper Street Palo Alto, CA 94301 650-473-3173 www.patriciawongmd.com Make Love Not Warts Genital Warts Genital warts are the most common sexually transmitted disease. The lifetime

More information

Reduction of HIV-1 RNA Levels with Therapy to Suppress Herpes Simplex Virus

Reduction of HIV-1 RNA Levels with Therapy to Suppress Herpes Simplex Virus T h e n e w e ng l a nd j o u r na l o f m e dic i n e original article Reduction of HIV-1 RNA Levels with Therapy to Suppress Herpes Simplex Virus Nicolas Nagot, M.D., Abdoulaye Ouédraogo, M.D., Vincent

More information

Final publishable summary report

Final publishable summary report Evaluation and impact of screening and treatment approaches for the prevention of cervical neoplasia in HIVpositive women in Burkina Faso and South Africa EC Grant Agreement Number: 265396 Final publishable

More information

Documented Analysis of HIV Care and Treatment Data. Workshop Report

Documented Analysis of HIV Care and Treatment Data. Workshop Report Documented Analysis of HIV Care and Treatment Data Workshop Report Dar es Salaam, Tanzania December 2017 Jim Todd Richelle Harklerode Paul Mee Funding for this work was provided by the Bill and Melinda

More information

The Promise of HIV Prevention in Pregnancy. Richard H. Beigi, MD., MSc. University of Pittsburgh Pittsburgh, PA USA

The Promise of HIV Prevention in Pregnancy. Richard H. Beigi, MD., MSc. University of Pittsburgh Pittsburgh, PA USA The Promise of HIV Prevention in Pregnancy Richard H. Beigi, MD., MSc. University of Pittsburgh Pittsburgh, PA USA Outline Pregnancy/Lactation Brief background Where we were Where we are now Where we are

More information